201 related articles for article (PubMed ID: 35614939)
1. Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.
Lin C; Yu B; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
Front Pharmacol; 2022; 13():880508. PubMed ID: 35614939
[No Abstract] [Full Text] [Related]
2. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
[TBL] [Abstract][Full Text] [Related]
3. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
Kong M; Peng Y; Qiu L
Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
5. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
Li H; Xi Y; Liu H; Xin X
Front Nutr; 2022; 9():914079. PubMed ID: 36091227
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.
Gai Z; Gui T; Alecu I; Lone MA; Hornemann T; Chen Q; Visentin M; Hiller C; Hausler S; Kullak-Ublick GA
Liver Int; 2020 Apr; 40(4):844-859. PubMed ID: 31883408
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
[TBL] [Abstract][Full Text] [Related]
9. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
[TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
12. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
[TBL] [Abstract][Full Text] [Related]
14. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
15. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling.
Azizsoltani A; Hatami B; Zali MR; Mahdavi V; Baghaei K; Alizadeh E
Biomed Pharmacother; 2023 Dec; 168():115777. PubMed ID: 37913732
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of farnesoid X receptor agonists.
Ali AH; Carey EJ; Lindor KD
Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity.
Yang Y; Yuan W; He K; Lin C; Du S; Kou Y; Nie B
Front Pharmacol; 2024; 15():1366479. PubMed ID: 38595921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
